more direct and favorable effect on cardiac structure and function. Along these lines, previous studies have demonstrated that higher levels of cardiorespiratory fitness are associated with more favorable left ventricular geometry, less diastolic stiffness, and reduced left ventricular filling pressures. 9, 10 Another potential explanation for the inverse associations between physical activity and HFpEF may be reverse causation, such that lower levels of physical activity represent a marker for more severe disease and a higher burden of comorbidities. This is supported by the observation that the inverse association between physical activity and risk of adverse outcomes was significant only in short-term follow-up and attenuated beyond the first 2 years. Furthermore, recent work from the NEAT-HF trial (Nitrate's Effect on Activity Tolerance in Heart Failure) demonstrated that individuals with lower levels of objectively measured physical activity had a higher burden of comorbidities.
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The present study findings have implications for future research because they support the hypothesis that exercise training might improve outcomes among patients with HFpEF. Recent work from our group suggests that the benefits of exercise are much more apparent among patients with HFpEF than HFrEF. Specifically, we observed that 12 weeks of exercise training was associated with 19% improvement in peak VO2 among HFpEF patients and no improvement in peak VO2 in HFrEF patients. 12 Nevertheless, supervised exercise in cardiac rehab is only approved for HFrEF. Given the modest impact of exercise training observed in HF-ACTION, 13 taken together, these data suggest that we may be exercising the wrong HF patients. Thus, a clinical trial comparing exercise training versus usual care is warranted-an HF-ACTION trial for HFpEF.
These findings also have implications for clinical practice. In the absence of established therapies for the prevention and treatment of HFpEF, we should be emphasizing to patients the importance of achieving or exceeding the guideline-recommended doses of physical activity. Exercise is not a categorical yes/no variable, but rather can best be considered as a medicine as emphasized by the Exercise is Medicine campaign. For both HFpEF prevention and treatment, the preponderance of evidence suggests that doses more than the current recommendations may be necessary. Higher doses of exercise can be achieved by increasing the intensity of exercise or by increasing the duration of exercise. For patients with established HFpEF, achieving a higher dose of exercise may be best met by doubling the recommended duration of walking from 30 minutes to an hour a day.
We would like to congratulate Hegde et al for taking an important step in clarifying the prognostic role of physical activity levels among patients with HFpEF.
Future studies are needed to test whether modifying physical activity levels might modify risk in HFpEF patients. In the interim, in the absence of documented treatments for these patients, this study reminds us that we may already have one of the safest and cost-effective therapies available for HFpEF patients. Shouldn't we be prescribing it?
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